Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Spurgeon

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA

Hematological Oncology

English

Stabilization of a Fractional-Order Chain of Integrators: A Contraction-Based Approach

IMA Journal of Mathematical Control and Information

English

Related publications

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma: A Phase II Multicenter Study of the Fondazione Italiana Linfomi

Haematologica

Hematology

2018

English

Combination of Ibrutinib With Rituximab (Ir) Is Highly Effective in Previously Untreated Elderly (>65 Years) Patients (Pts) With Mantle Cell Lymphoma (Mcl) - Phase Ii Trial

Hematological Oncology

English

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

British Journal of Haematology

Hematology

2018

English

Maintenance Rituximab Is Associated With Improved Overall Survival in Mantle Cell Lymphoma Patients Responding to Induction Therapy With Bendamustine + Rituximab (Br)

Hematological Oncology

English

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Hematological Oncology

English

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

British Journal of Haematology

Hematology

2018

English

Chronic Hepatitis E in Patients With Indolent Lymphoma After Treatment With Rituximab and Bendamustine

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

A Retrospective Study Evaluating the Efficacy and Safety of Bendamustine in the Treatment of Mantle Cell Lymphoma

Leukemia and Lymphoma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Spurgeon

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA

Stabilization of a Fractional-Order Chain of Integrators: A Contraction-Based Approach

Related publications

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma: A Phase II Multicenter Study of the Fondazione Italiana Linfomi

Combination of Ibrutinib With Rituximab (Ir) Is Highly Effective in Previously Untreated Elderly (>65 Years) Patients (Pts) With Mantle Cell Lymphoma (Mcl) - Phase Ii Trial

Bendamustine and Rituximab in Elderly Patients With Low-Tumour Burden Follicular Lymphoma. Results of the LYSA Phase II BRIEF Study

Maintenance Rituximab Is Associated With Improved Overall Survival in Mantle Cell Lymphoma Patients Responding to Induction Therapy With Bendamustine + Rituximab (Br)

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

Chronic Hepatitis E in Patients With Indolent Lymphoma After Treatment With Rituximab and Bendamustine

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

A Retrospective Study Evaluating the Efficacy and Safety of Bendamustine in the Treatment of Mantle Cell Lymphoma